Literature DB >> 31181953

Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation.

Gaurav Gulati1, E Wilson Grandin2,3, Kevin Kennedy3, Fausto Cabezas2, David D DeNofrio1, Robb Kociol4, J Eduardo Rame5, Francis D Pagani6, James K Kirklin7, Robert L Kormos8, Jeffrey Teuteberg9, Michael Kiernan1.   

Abstract

Background Early right heart failure (RHF) occurs commonly in left ventricular assist device (LVAD) recipients, and increased right ventricular (RV) afterload may contribute. Selective pulmonary vasodilators, like phosphodiesterase-5 inhibitors (PDE5i), are used off-label to reduce RV afterload before LVAD implantation, but the association between preoperative PDE5i use and early RHF after LVAD is unknown. Methods and Results We analyzed adult patients from the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support) who received a continuous flow LVAD after 2012. Patients on PDE5i were propensity-matched 1:1 to controls. The primary outcome was the incidence of severe early RHF, defined as the composite of death from RHF within 30 days, need for RV assist device support within 30 days, or use of inotropes beyond 14 days. Of 11 544 continuous flow LVAD recipients, 1199 (10.4%) received preoperative PDE5i. Compared to controls, patients on PDE5i had higher pulmonary artery systolic pressure (53.4 mm Hg versus 49.5 mm Hg) and pulmonary vascular resistance (2.6 WU versus 2.3 WU; P<0.001 for both). Before propensity matching, the incidence of severe early RHF was higher among patients on PDE5i than in controls (29.4% versus 23.1%; unadjusted odds ratio (OR), 1.32; 95% CI, 1.17-1.50). This association persisted after propensity matching (PDE5i, 28.9% versus control 23.7%; OR, 1.31; 95% CI, 1.09-1.57), driven by a higher incidence of prolonged inotropic support. Similar results were observed across a wide range of subgroups stratified by markers of pulmonary vascular disease and RV dysfunction. Conclusions Patients treated with preoperative PDE5i had markers of increased RV afterload and HF severity compared to unmatched controls. Even after propensity matching, patients receiving preimplant PDE5i therapy had higher rates of post-LVAD RHF.

Entities:  

Keywords:  heart failure; incidence; pulmonary artery; risk factors; vascular resistance

Mesh:

Substances:

Year:  2019        PMID: 31181953      PMCID: PMC6624075          DOI: 10.1161/CIRCHEARTFAILURE.118.005537

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  41 in total

1.  The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia.

Authors:  Julian P J Halcox; Khaled R A Nour; Gloria Zalos; Rita A Mincemoyer; Myron Waclawiw; Candido E Rivera; Georgia Willie; Samer Ellahham; Arshed A Quyyumi
Journal:  J Am Coll Cardiol       Date:  2002-10-02       Impact factor: 24.094

2.  Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.

Authors:  Gregory D Lewis; Justine Lachmann; Janice Camuso; John J Lepore; Jordan Shin; Maryann E Martinovic; David M Systrom; Kenneth D Bloch; Marc J Semigran
Journal:  Circulation       Date:  2006-12-18       Impact factor: 29.690

3.  Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation.

Authors:  Ingibjörg J Gudmundsdóttir; Sarah J McRobbie; Simon D Robinson; David E Newby; Ian L Megson
Journal:  Biochem Biophys Res Commun       Date:  2005-11-11       Impact factor: 3.575

4.  Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices.

Authors:  Charles T Klodell; Timothy E Morey; Emilio B Lobato; Juan M Aranda; Edward D Staples; Richard S Schofield; Philip J Hess; Tomas D Martin; Thomas M Beaver
Journal:  Ann Thorac Surg       Date:  2007-01       Impact factor: 4.330

5.  Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil.

Authors:  Vojtech Melenovsky; Hikmet Al-Hiti; Ludmila Kazdova; Antonin Jabor; Petr Syrovatka; Ivan Malek; Jiri Kettner; Josef Kautzner
Journal:  J Am Coll Cardiol       Date:  2009-08-11       Impact factor: 24.094

6.  Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure.

Authors:  Jamshid Alaeddini; Patricia A Uber; Myung H Park; Robert L Scott; Hector O Ventura; Mandeep R Mehra
Journal:  Am J Cardiol       Date:  2004-12-01       Impact factor: 2.778

7.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.

Authors:  Milton Packer; John McMurray; Barry M Massie; Abraham Caspi; Vincent Charlon; Alain Cohen-Solal; Wolfgang Kiowski; William Kostuk; Henry Krum; Barry Levine; Paolo Rizzon; Jordi Soler; Karl Swedberg; Susan Anderson; David L Demets
Journal:  J Card Fail       Date:  2005-02       Impact factor: 5.712

8.  Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

Authors:  Gregory D Lewis; Ravi Shah; Khurram Shahzad; Janice M Camuso; Paul P Pappagianopoulos; Judy Hung; Ahmed Tawakol; Robert E Gerszten; David M Systrom; Kenneth D Bloch; Marc J Semigran
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

9.  The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates.

Authors:  Jennifer Cowger Matthews; Todd M Koelling; Francis D Pagani; Keith D Aaronson
Journal:  J Am Coll Cardiol       Date:  2008-06-03       Impact factor: 24.094

10.  Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.

Authors:  Jayan Nagendran; Stephen L Archer; Daniel Soliman; Vikram Gurtu; Rohit Moudgil; Alois Haromy; Chantal St Aubin; Linda Webster; Ivan M Rebeyka; David B Ross; Peter E Light; Jason R B Dyck; Evangelos D Michelakis
Journal:  Circulation       Date:  2007-07-02       Impact factor: 29.690

View more
  9 in total

Review 1.  Emerging therapies for right ventricular dysfunction and failure.

Authors:  Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

2.  Pulmonary Vasculature Responsiveness to Phosphodiesterase-5A Inhibition in Heart Failure With Reduced Ejection Fraction: Possible Role of Plasma Potassium.

Authors:  Luca Monzo; Adrian Reichenbach; Hikmet Al-Hiti; Ivana Jurcova; Zuzana Huskova; Josef Kautzner; Vojtech Melenovsky
Journal:  Front Cardiovasc Med       Date:  2022-05-26

Review 3.  Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety.

Authors:  Sumon Roy; Robert A Kloner; Fadi N Salloum; Ion S Jovin
Journal:  Cardiovasc Drugs Ther       Date:  2021-10-15       Impact factor: 3.947

Review 4.  Predicting, Recognizing, and Treating Right Heart Failure in Patients Undergoing Durable LVAD Therapy.

Authors:  Teresa S Wang; Marisa Cevasco; Edo Y Birati; Jeremy A Mazurek
Journal:  J Clin Med       Date:  2022-05-25       Impact factor: 4.964

5.  Understanding Longitudinal Changes in Pulmonary Vascular Resistance After Left Ventricular Assist Device Implantation.

Authors:  Gaurav Gulati; Robin Ruthazer; David Denofrio; Amanda R Vest; David Kent; Michael S Kiernan
Journal:  J Card Fail       Date:  2021-01-12       Impact factor: 5.712

6.  Outcomes With Phosphodiesterase-5 Inhibitor Use After Left Ventricular Assist Device: An STS-INTERMACS Analysis.

Authors:  E Wilson Grandin; Gaurav Gulati; Jose I Nunez; Kevin Kennedy; J Eduardo Rame; Pavan Atluri; Francis D Pagani; James K Kirklin; Robert L Kormos; Jeffrey Teuteberg; Michael S Kiernan
Journal:  Circ Heart Fail       Date:  2022-03-25       Impact factor: 10.447

7.  Phosphodiesterase-5 Inhibitor Therapy for Left Ventricular Assist Device Patients: More Data, More Questions.

Authors:  Gaurav Gulati; Michael S Kiernan
Journal:  J Am Heart Assoc       Date:  2020-07-10       Impact factor: 5.501

8.  Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation.

Authors:  Andrew Xanthopoulos; Konstantinos Tryposkiadis; Filippos Triposkiadis; Kiyotaka Fukamachi; Edward G Soltesz; James B Young; Kathy Wolski; Eugene H Blackstone; Randall C Starling
Journal:  J Am Heart Assoc       Date:  2020-07-10       Impact factor: 5.501

9.  Predictors and prognosis of right ventricular function in pulmonary hypertension due to heart failure with reduced ejection fraction.

Authors:  Alexander Schmeißer; Thomas Rauwolf; Thomas Groscheck; Katharina Fischbach; Siegfried Kropf; Blerim Luani; Ivan Tanev; Michael Hansen; Saskia Meißler; Kerstin Schäfer; Paul Steendijk; Ruediger C Braun-Dullaeus
Journal:  ESC Heart Fail       Date:  2021-05-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.